X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TTX-810 is an IND-enabling candidate, a MCL1 inhibitor, a highly potent and selective macrocyclic compound to treat patients with solid tumor or hematological cancers.
Lead Product(s): TTX-810
Therapeutic Area: Oncology Product Name: TTX-810
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Broad Institute of Harvard
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
Previous trials with ANJ900 demonstrated clinically meaningful glucose lowering with only one-third the plasma concentrations observed with currently marketed formulations of metformin.
Lead Product(s): Metformin
Therapeutic Area: Endocrinology Product Name: ANJ900
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Population Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 19, 2022
Details:
ANJ900 (Metformin) is a gut-targeted formulation designed to lower glucose with reduced systemic exposure of metformin, so that patients who cannot take currently available formulations of metformin may achieve better glucose control.
Lead Product(s): Metformin
Therapeutic Area: Endocrinology Product Name: ANJ900
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
ANJ908 (pradigastat) is an inhibitor of diacylglycerol acyltransferase 1 (DGAT1), which plays a key role in the re-assembly of meal triglycerides and acts as a sensor of dietary fat intake.
Lead Product(s): Pradigastat
Therapeutic Area: Gastroenterology Product Name: ANJ908
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
Anji subsidiary has acquired worldwide development and commercialization rights to an MCL1 inhibitor (ANJ810) program through a license from the Broad Institute of MIT and Harvard and will work to advance the program’s MCL1 inhibitors through clinical development.
Lead Product(s): ANJ810
Therapeutic Area: Oncology Product Name: ANJ810
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Broad Institute of MIT
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 17, 2021
Details:
Anji Pharma has initiated a pivotal trial of ANJ900 (delayed-release metformin) in patients with Type 2 diabetes (T2D), including those with varying stages of renal disease.
Lead Product(s): Metformin
Therapeutic Area: Endocrinology Product Name: ANJ900
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
